
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)12376-6
10.1016/j.heliyon.2024.e36345
e36345
Research Article
Efficacy of anti-hyperkalemic agents during cardiopulmonary resuscitation in out-of-hospital cardiac arrest
Lee Gun Tak ab
Jeong Daun a
Park Jong Eun ab
Lee Se Uk a
Kim Taerim a
Yoon Hee a
Cha Won Chul a
Sim Min Seob a
Jo Ik Joon a
Hwang Sung Yeon sygood.hwang@samsung.com
a⁎⁎
Shin Tae Gun tackles@naver.com
a⁎
a Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
b Department of Emergency Medicine, College of Medicine, Kangwon National University, Chuncheon, Gangwon-do, Republic of Korea
⁎ Corresponding author. Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. tackles@naver.com
⁎⁎ Corresponding author. Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. sygood.hwang@samsung.com
15 8 2024
30 8 2024
15 8 2024
10 16 e3634510 2 2023
11 7 2024
14 8 2024
© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Aim

We assessed the efficacy of anti-hyperkalemic agents for alleviating hyperkalemia and improving clinical outcomes in patients with out-of-hospital cardiac arrest (OHCA).

Methods

This was a single-center, retrospective observational study of OHCA patients treated at tertiary hospitals between 2010 and 2020. Adult patients aged 18 or older who were in cardiac arrest at the time of arrival and had records of potassium levels measured during cardiac arrest were included. A linear regression model was used to evaluate the relationship between changes in potassium levels and use of anti-hyperkalemic medications. Cox proportional hazards regression analysis was performed to analyze the relationship between the use of anti-hyperkalemic agents and the achievement of return of spontaneous circulation (ROSC).

Results

Among 839 episodes, 465 patients received anti-hyperkalemic medication before ROSC. The rate of ROSC was higher in the no anti-hyperkalemic group than in the anti-hyperkalemic group (55.9 % vs 47.7 %, P = 0.019). The decrease in potassium level in the anti-hyperkalemic group from pre-ROSC to post-ROSC was significantly greater than that in the no anti-hyperkalemic group (coefficient 0.38, 95 % confidence interval [CI], 0.13–0.64, P = 0.003). In Cox proportional hazards regression analysis, the use of anti-hyperkalemic medication was related to a decreased ROSC rate in the overall group (adjusted hazard ratio [aHR] 0.66, 95 % CI, 0.54–0.81, P < 0.001), but there were no differences among subgroups classified according to initial potassium levels.

Conclusions

Anti-hyperkalemic agents were associated with substantial decreases in potassium levels in OHCA patients. However, administration of anti-hyperkalemic agents did not affect the achievement of ROSC.

Keywords

Hyperkalemia
Cardiac arrest
Calcium
Sodium bicarbonate
==== Body
pmcAbbreviations

OHCA (out-of-hospital cardiac arrest)

CPR (cardiopulmonary resuscitation)

ECG (electrocardiogram)

ED (emergency department)

IHD (ischemic heart disease)

CKD (chronic kidney disease)

ROSC (return of spontaneous circulation)

IQR (interquartile range)

HR (hazard ratio)

CI (confidence interval)

1 Introduction

Globally, out-of-hospital cardiac arrest (OHCA) is a significant public health problem with a poor prognosis [[1], [2], [3]]. Despite advancements in resuscitation care, the likelihood of survival for OHCA patients with a favorable neurological outcome are still low [[1], [2], [3], [4], [5]]. To improve the prognosis of patients with OHCA, international guidelines recommend investigating and treating the etiology of reversible cardiac arrest in addition to high-quality cardiopulmonary resuscitation (CPR) [6,7].

Hyperkalemia is a hazardous electrolyte imbalance that can result in cardiac arrest by producing deadly arrhythmias [[8], [9], [10], [11]]. Potassium is the principal intracellular cation, with approximately 98 % of it distributed within the intracellular space [12,13]. The allocation of total body potassium between the intracellular and extracellular spaces establishes a notable potassium concentration gradient between these two compartments. The electrical characteristics of cells can be significantly changed by even minor adjustments in the smaller extracellular concentration of potassium, due to the dependence of membrane resting potential on the ratio of intracellular and extracellular potassium concentrations [14]. Hyperkalemia is hazardous because it can cause depolarization in cell membranes that are electrically active, including cardiac and skeletal muscle [15,16]. The myocardium is highly sensitive to changes in potassium concentration. Imbalances in the potassium concentration gradient during hyperkalemia can lead to a series of abnormalities in the ECG [17]. Early electrocardiographic indicators include peaked T waves on the ECG followed by flattened or absent T waves, a longer PR interval, a widened QRS complex, deepened S waves, and the merging of S and T waves. As hyperkalemia continues, the ECG can develop a sine-wave pattern, and the patient can go into cardiac arrest [10,18,19]. Several interventions have been proposed for life-threatening hyperkalemia, including intravenous calcium, bicarbonate, and insulin with glucose [[6], [7], [8],20]. It remains unclear, however, if such interventions provided during CPR effectively reduce serum potassium levels and thereby improve the patient's prognosis [[21], [22], [23], [24], [25], [26]]. This study's objective was to assess the efficacy of anti-hyperkalemic medicines in treating hyperkalemia and improving clinical outcomes.

2 Methods

2.1 Study design and population

This was a retrospective, observational study of OHCA patients treated at Samsung Medical Center (a 1960-bed, university-affiliated, tertiary referral hospital with an annual census of 70,000 located in Seoul, South Korea), from January 2010 to December 2020. The primary analysis included adult patients who experienced OHCA and were 18 years of age or older. Both shockable and non-shockable initial ECG rhythms were included in the analysis. Excluded from the study were cases in which patients achieved return of spontaneous circulation (ROSC) before reaching the hospital and were not in cardiac arrest upon arrival, as well as cases in which CPR was not performed at the hospital due to patients having limitations on resuscitation, such as a do-not-resuscitate order. In addition, cases whose potassium concentration was not measured during CPR were also excluded. This study was approved by the Institutional Review Board of Samsung Medical Center (IRB No.: 2022-04-130). The need for informed consent was waived given the study's retrospective, observational, and anonymous nature.

2.2 Data collection and outcome measures

The following variables were extracted from the institutional cardiac arrest registry and electronic medical records: age, sex, preexisting conditions including hypertension, diabetes, chronic pulmonary disease, ischemic heart disease (IHD), malignancy, and chronic kidney disease (CKD), initial ECG rhythm, witnessed cardiac arrest, bystander-provided CPR, arrest location, laboratory test results including pH, HCO3, and potassium levels, medications including sodium bicarbonate, calcium gluconate, insulin with glucose, and epinephrine, ROSC, one-month survival, and three-month survival. To investigate changes in potassium level during CPR, the initial potassium level during CPR, subsequent potassium levels during CPR, and potassium levels after ROSC were compared. In this study, ROSC was defined as palpable pulse at any time. In the event of multiple cardiac arrests, ROSC was defined as the first palpable pulse. Changes in potassium level (delta potassium) were also compared between each measurement time point. When potassium levels were measured multiple times during CPR, the first value measured after the initial measurement was used for analysis; this is referred to as the subsequent level. The interval to potassium concentration measurement was defined as the time between the patient's arrival at the ED and the measurement report. Electronic medical data were extracted from the Clinical Data Warehouse DARWIN-C of Samsung Medical Center for this study. We analyzed anonymized clinical data and performed no manipulations on the original data other than statistical analysis.

The anti-hyperkalemic group comprised individuals who received any potassium lowering agents such as sodium bicarbonate, calcium, or insulin with glucose, whereas the no anti-hyperkalemic group comprised individuals who did not receive any of the medications listed above. Aside from the American Heart Association (AHA) recommendation, no institute-specific protocol was used to treat hyperkalemia in patients with cardiac arrest; drug administration was left to the discretion of the clinician. The primary outcome of this study was the ROSC rate.

2.3 Statistical analysis

Baseline characteristics of groups are reported as median values and interquartile ranges (IQRs) for continuous variables and as numbers and percentages for categorical variables. Groups were compared using Wilcoxon rank-sum tests for continuous variables and chi-squared tests for categorical variables. The Wilcoxon signed-rank test was used to compare repeated measured potassium levels. The relationship between delta potassium level and use of anti-hyperkalemic medication was evaluated using a linear regression model. The log-rank test was used to compare Kaplan-Meier curves for the achievement of ROSC according to the use of anti-hyperkalemic medication. The relationship between ROSC and usage of anti-hyperkalemic medication in the presence of moderate to severe hyperkalemia was assessed using Cox proportional hazards regression analysis and results are expressed as hazard ratios (HRs) and 95 % confidence intervals (CIs). Moderate to severe hyperkalemia was defined as potassium levels of 6.5 mmol/L or higher. Adjustments were made for variables with significant differences between groups and variables known to be prognostic factors. Age, gender, diabetes, malignancy, CKD, chronic pulmonary disease, arrest location, bystander CPR, bystander witnessed, initial ECG rhythm, and initial potassium level were the final variables included. In addition, a subgroup analysis was performed for individuals with potassium levels of 6.5 mmol/L or higher, 7.5 mmol/L or higher, and 8.5 mmol/L or higher to validate the effects of anti-hyperkalemic agents based on the degree of hyperkalemia. The predicted level of potassium during CPR is presented as a 95 % CI and was generated using a quadratic prediction plot referencing all potassium levels measured during CPR. P-values less than 0.05 were considered statistically significant. STATA software (STATA Corporation, College Station, TX, USA) version 17.0 was used to analyze the data.

3 Results

3.1 Baseline characteristics

In this study, we assessed the eligibility of 1370 OHCA patients. Among them, 66 patients were not in cardiac arrest upon arrival at the ED, and in 465 patients, serum potassium levels were not measured during CPR. After excluding these cases, 839 OHCA cases were analyzed. The anti-hyperkalemic treatment group comprised 465 cases while the no anti-hyperkalemic group comprised 374 cases. Calcium was the most commonly used drug among the 465 individuals in the anti-hyperkalemic group (N = 369/465, 79.4 %), followed by sodium bicarbonate (N = 321/465, 69.0 %) and insulin (N = 64/465, 13.8 %).

Table 1 shows the baseline characteristics of the study population. The median age of the study population was 68 years, and 65.1 % of the participants were male (n = 546). There were no statistically significant differences in age (no anti-hyperkalemic vs anti-hyperkalemic: 67 years [IQR 53–78] vs 68 years [IQR 53–80], P = 0.275) or gender (no anti-hyperkalemic vs anti-hyperkalemic: 63.6 % vs 66.2 %, P = 0.432) between the two groups. Diabetes (24.3 % vs 16.3 %, P = 0.005), chronic kidney disease (8.6 % vs 2.9 %, P = 0.001), and malignancy (18.5 % vs 11.8 %, P = 0.007) were more prevalent in the anti-hyperkalemic group than in the no anti-hyperkalemic group. In contrast, the prevalence of chronic pulmonary disease was higher in the no anti-hyperkalemic group than in the anti-hyperkalemic group (4 % vs 1.7 %, P = 0.043). Cardiac arrest occurred more frequently in private places in the anti-hyperkalemic group than in the no anti-hyperkalemic group (56.5 % vs 64.6 %, P = 0.018).Table 1 Baseline characteristics of all patients.

Table 1	Overall (n = 839)	No anti-hyperkalemic (n = 374)	Anti-hyperkalemic (n = 465)	P	
Age, years	68 (53–79)	67 (53–78)	68 (53–80)	0.275	
Male sex, no. (%)	546 (65.1 %)	238 (63.6 %)	308 (66.2 %)	0.432	
Preexisting conditions, no. (%)	
 Hypertension	270 (32.2 %)	119 (31.8 %)	151 (32.5 %)	0.840	
 Diabetes	174 (20.7 %)	61 (16.3 %)	113 (24.3 %)	0.005	
 Chronic pulmonary disease	23 (2.7 %)	15 (4.0 %)	8 (1.7 %)	0.043	
 IHD	68 (8.1 %)	28 (7.5 %)	40 (8.6 %)	0.556	
 Malignancy	130 (15.5 %)	44 (11.8 %)	86 (18.5 %)	0.007	
 CKD	51 (6.1 %)	11 (2.9 %)	40 (8.6 %)	0.001	
 CVA	68 (8.1 %)	28 (7.5 %)	40 (8.6 %)	0.556	
Arrest location, no. (%)				0.018	
 Private place	504 (60.9 %)	209 (56.5 %)	295 (64.6 %)		
 Public place	323 (39.1 %)	161 (43.5 %)	162 (35.5 %)		
Bystander witnessed, no. (%)	574 (70.6 %)	271 (73.8 %)	303 (69.4 %)	0.066	
Bystander CPR, no. (%)	365 (44.3 %)	165 (45.2 %)	200 (43.6 %)	0.639	
Initial ECG rhythm, no. (%)	
 Shockable	65 (7.8 %)	26 (7.0 %)	39 (8.4 %)	0.441	
 Non-shockable	772 (92.2 %)	347 (93.0 %)	425 (91.6 %)	0.544	
Initial pH level	6.92 (6.80–7.04)	6.96 (6.84–7.08)	6.89 (6.79–6.99)	<0.001	
Epinephrine use, no. (%)	820 (97.7 %)	355 (94.9 %)	465 (100.0 %)	<0.001	
IHD, ischemic heart disease; CKD, chronic kidney disease; CVA, cerebrovascular accident; CPR, cardiopulmonary resuscitation; ECG, electrocardiogram.

3.2 Comparisons of potassium levels

Initial and subsequent potassium levels during CPR were measured at 7 (IQR 3–9) and 16 (IQR 11–20) minutes following the initiation of CPR (Fig. 1, Supplementary Fig. 1 and Supplementary Table A). Potassium levels were highest initially (6.2 mmol/L, IQR 5.0–7.8) and decreased significantly subsequently and post-ROSC (5.7 mmol/L, IQR 4.4–7.2; 5.1 mmol/L, IQR 4.0–6.3) (Fig. 1A & Supplementary Table A). Subsequent potassium levels were significantly lower than initial levels in both groups. In the anti-hyperkalemic group, post-ROSC levels were significantly lower than subsequent levels (P = 0.02), while post-ROSC levels were no different from subsequent levels in the no anti-hyperkalemic group (P = 0.60) (Fig. 1B and C).The anti-hyperkalemic group had significantly higher initial (6.9 mmol/L [IQR 5.7–8.4] vs 5.4 mmol/L [IQR 4.6–6.6], P < 0.001), subsequent (6.3 mmol/L [IQR 5.0–8.0] vs 4.7 mmol/L [IQR 3.9–5.7], P < 0.001), and post-ROSC (5.4 mmol/L [IQR 4.4–6.8] vs 4.5 mmol/L [IQR 3.6–5.7], P < 0.001) potassium levels than the no anti-hyperkalemic group.Fig. 1 Initial (A), subsequent (B), and post ROSC (C) potassium levels (*P < 0.05). Initial refers to the first measured value during CPR. Subsequent refers to the value that is measured during CPR after the initial measurement. Post ROSC refers to the first measured value after ROSC.

Fig. 1

When delta potassium levels were compared, potassium level variation from the initial measurement to the post-ROSC measurement was significantly greater in the anti-hyperkalemic group than the no anti-hyperkalemic group (coefficient 0.38, 95 % CI, 0.13–0.64, P = 0.003). However, there was no discernible difference between the two groups in the changes in potassium levels from initial to subsequent and from subsequent to post-ROSC time periods (coefficient 0.21, 95 % CI, −0.14–0.56, P = 0.234) (Supplementary Table B).

Predicted potassium levels during CPR are shown in Fig. 2. Overall, while CPR was continued, there was a decrease in the concentration of potassium (Fig. 2A). The potassium level in the no anti-hyperkalemic group appeared to rise steadily for the first 10 min of CPR, and then began to decrease (Fig. 2B). In contrast, the potassium level in the anti-hyperkalemic group showed a consistent decline throughout CPR (Fig. 2C).Fig. 2 Fitted curve of the predictive potassium level for overall (A), no-anti hyperkalemic group (B) and anti-hyperkalemic group (C). A quadratic prediction plot was generated to visualize the relationship between potassium levels and ROSC, incorporating all potassium levels measured during CPR.

Fig. 2

3.3 Outcomes

The rate of ROSC was higher in the no anti-hyperkalemic group than in the anti-hyperkalemic group (55.9 % vs 47.7 %, P = 0.019). The interval to ROSC was longer in the anti-hyperkalemic group (7 min [IQR 5–11] vs 10 min [IQR 7–16], P < 0.001). In addition, in the no anti-hyperkalemic group, survival to ER discharge was significantly higher (34.2 % vs 22.3 %, P < 0.001) than in the anti-hyperkalemic group. However, neither 3-month survival nor favorable neurology differed significantly between groups (Table 2).Table 2 Outcomes.

Table 2	Overall (n = 839)	No anti-hyperkalemic (n = 374)	Anti-hyperkalemic (n = 465)	P	
ROSC	408 (48.6 %)	209 (55.9 %)	222 (47.7 %)	0.019	
Time to ROSCa, min	9 (6–11)	7 (5–11)	10 (7–16)	<0.001	
Survival to ER discharge	227 (27.1 %)	128 (34.2 %)	99 (22.3 %)	<0.001	
3-month survival	29 (3.5 %)	17 (4.6 %)	12 (2.6 %)	0.121	
3-month survival with favorable neurologic outcome	25 (3.0 %)	14 (3.7 %)	11 (2.4 %)	0.243	
a Duration between the initiation of advanced cardiovascular life support and the restoration of spontaneous circulation (ROSC).

The rates of achievement of ROSC over time for the overall group and for groups stratified by initial potassium level are depicted in the Kaplan Meier plot in Fig. 3. The overall no anti-hyperkalemic group had a higher ROSC rate (log-rank test, P < 0.001) (Fig. 3A), whereas the anti-hyperkalemic group with a high initial potassium level had a higher ROSC rate in subgroup analysis, but none of the subgroup results were significant (Fig. 3B–D).Fig. 3 Kaplan-Meier plot depicting proportion of ROSC according to initial potassium level.

Fig. 3

Findings of univariable and multivariable Cox regression analyses to evaluate the association between ROSC and the administration of anti-hyperkalemic drugs based on a specific initial potassium level are shown in Table 3. The use of anti-hyperkalemic medications was not associated with ROSC rate in any subgroup (all P > 0.05). In the subgroup analysis involving individuals with moderate to severe hyperkalemia, there was a significant correlation between witnessed cardiac arrest and the achievement of ROSC in the group with potassium levels above 6.5 mmol/L (adjusted hazard ratio [aHR] 2.17, 95 % CI, 1.46–3.22, P < 0.001) and above 7.5 mmol/L (adjusted hazard ratio [aHR] 2.40, 95 % CI, 1.42–4.06, P = 0.001). However, this correlation was not significant in the group with potassium levels above 8.5 mmol/L (adjusted hazard ratio [aHR] 1.53, 95 % CI, 0.766–3.10, P = 0.229). Hyperkalemia is not only responsible for cardiac arrest but also closely correlated with the duration of the cardiac arrest. Therefore, to consider variations in potassium levels based on the timing of cardiac arrest, an additional analysis was conducted, taking into account the duration from the onset of cardiac arrest to arrival at the hospital in individuals with witnessed cardiac arrest whose exact time of cardiac arrest was known (Supplementary Table C). Within this subgroup analysis, no observed correlation was found between the use of anti-hyperkalemic drugs and the ROSC rate in any of the potassium level groups (all P > 0.05).Table 3 Univariable and multivariable Cox regression analyses predicting ROSC following administration of anti-hyperkalemic medications.

Table 3	Unadjusted HR	95 % CI	P	Adjusted HR	95 % CI	P	
Overall group (N = 838)	0.70	0.58–0.85	<0.001	0.66	0.54–0.81	<0.001	
K ≥ 6.5 mmol/L (N = 382)	1.05	0.73–1.53	0.781	0.96	0.65–1.41	0.823	
K ≥ 7.5 mmol/L (N = 249)	1.43	0.82–2.49	0.210	1.25	0.69–2.24	0.461	
K ≥ 8.5 mmol/L (N = 153)	1.91	0.80–4.56	0.147	1.92	0.73–5.04	0.187	

4 Discussion

Cardiac arrest is a condition in which circulation is severely impaired, and even with high-quality CPR performed by trained rescuers, cardiac output is only 10–30 % of normal [27,28]. As a result of the patient's drastically altered metabolism, medications administered during cardiac arrest may have different effects than when they are used under normal circumstances. In most patients who survive cardiac arrest, spontaneous circulation is restored within 20–30 min of CPR, but the likelihood of resuscitation decreases significantly if cardiac arrest persists [[29], [30], [31]]. Because of these factors, it is difficult to determine whether the medication administered during CPR has the desired impact within a limited period of time. The purpose of this study was to evaluate whether anti-hyperkalemic agents administered during CPR were effective at lowering serum potassium levels and if they were associated with an improved clinical outcome.

Our main finding in this study was that the administration of anti-hyperkalemic agents during CPR for OHCA did lower serum potassium levels to a greater extent than in cases when these agents were not used, but this did not affect achievement of ROSC nor improve clinical outcomes. Our findings support those of prior studies that reported that neither calcium nor sodium bicarbonate improved the clinical outcomes of cardiac arrest victims [21,[23], [24], [25], [26]]. Existing studies, however, have focused on medications routinely administered to cardiac arrest patients or used in situations of protracted cardiac arrest, and more evidence regarding the use of anti-hyperkalemic agents in cardiac arrest with hyperkalemia is required.

Hyperkalemia is a potentially dangerous electrolyte imbalance that may result in cardiac arrest. In a recent multicenter study, elevated serum potassium levels were associated with worse outcomes in OHCA patients [10]. Therefore, addressing hyperkalemia appropriately during cardiopulmonary resuscitation may have the potential to improve patient prognosis. In this study, the use of anti-hyperkalemic agents during CPR was associated with a decrease in potassium levels. In the anti-hyperkalemic group, the initial potassium level was significantly higher, and the ROSC rate was substantially lower, so we determined that hyperkalemia itself had an effect on the outcome rather than the effect of hyperkalemia medication. As a result, a sub-analysis was conducted in accordance with the potassium concentration. Nonetheless, the administration of anti-hyperkalemic agents did not significantly affect the ROSC rate in any subgroups categorized by the degree of hyperkalemia.

Giving calcium and sodium bicarbonate to patients with severe hyperkalemia improved their clinical prognosis in a previous study of in-hospital cardiac arrest patients [22]. We feel this is a similar pattern to that seen in this study, where the hazard ratios for ROSC increased in the group with higher blood potassium levels when anti-hyperkalemic drugs were used. Our research is noteworthy because we examined the efficacy of anti-hyperkalemic medicines at reducing blood potassium levels in out-of-hospital cardiac arrest patients as well as the influence of these lowered potassium levels on clinical outcomes. The effectiveness of anti-hyperkalemic medicines in cardiac arrest with hyperkalemia requires more investigation.

The following are some of the limitations of the study. First, because this study was performed in a single center, our findings may not be generalizable to other settings. In addition, the power of this investigation is limited by the relatively small sample size. Second, because this was a retrospective observational study with no intervention, selection bias is possible. Third, in the majority of our data, we were only able to verify the administration of anti-hyperkalemic drugs during the CPR process but were unable to access accurate records regarding the precise timing of drug administration. Hence, we were unable to evaluate the impact of drug administration time. Fourth, a substantial number of patients were omitted from the analysis because their potassium concentrations were never measured during CPR, most likely due to the short CPR time, which may have introduced bias. Fifth, the first ROSC was the study's primary endpoint. When determining a patient's actual prognosis, ROSC may be less important than survival discharge and neurologic outcome. However, the purpose of this study was to determine whether causes of fatal and correctable cardiac arrest could be effectively managed during resuscitation. If a correctable cause is not treated effectively, the patient's chances of recovering spontaneous circulation are drastically diminished. Therefore, we determined that the ROSC was a more appropriate primary endpoint for evaluating the effect of therapeutic drugs on hyperkalemia during CPR. In cases of repeated cardiac arrest, the first ROSC was chosen as the endpoint because we believed that evaluating the effects of drugs and blood potassium levels due to physiological changes in the state of spontaneous circulation would involve too many variables. Sixth, it is conceivable that patients with heterogeneous conditions, such as calcium blocker overdose and severe metabolic acidosis, were included in this study. Seventh, we did not comprehensively account for potential confounders, such as the time interval between the occurrence of cardiac arrest and the initiation of resuscitation or the delay in transportation. Additionally, even though we performed adjustments for the initial potassium concentration, we may have failed to make enough adjustments for the impact of hyperkalemia on ROSC. Similar to other retrospective studies, we did not account for variables such as CPR team skill or teamwork, or quality of chest compressions.

5 Conclusions

Anti-hyperkalemic agents significantly reduced potassium levels in OHCA patients but did not alter their clinical prognosis. The effectiveness of anti-hyperkalemic agents in CPR for OHCA patients with severe hyperkalemia warrants further study.

Availability of data and materials

The data and materials used in the current study are all available from the corresponding author upon reasonable request.

Funding

This work was supported by a 10.13039/501100003725 National Research Foundation of Korea grant (NRF-2020R1F1A1075904 ) funded by the Korean government.

Previous presentations

None.

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of Samsung Medical Center (IRB No.: 2022-04-130). The need for informed consent was waived given the study's retrospective, observational, and anonymous nature.

CRediT authorship contribution statement

Gun Tak Lee: Writing – original draft, Software, Conceptualization. Daun Jeong: Methodology, Investigation. Jong Eun Park: Methodology. Se Uk Lee: Data curation. Taerim Kim: Investigation. Hee Yoon: Data curation. Won Chul Cha: Investigation. Min Seob Sim: Validation, Software. Ik Joon Jo: Supervision. Sung Yeon Hwang: Writing – review & editing, Supervision. Tae Gun Shin: Writing – review & editing, Conceptualization.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Tae Gun Shin reports financial support was provided by 10.13039/501100003725 National Research Foundation of Korea . If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A Supplementary data

The following is/are the supplementary data to this article:Multimedia component 1

Multimedia component 1

Multimedia component 2

Multimedia component 2

Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2024.e36345.
==== Refs
References

1 Yan S. Gan Y. Jiang N. Wang R. Chen Y. Luo Z. The global survival rate among adult out-of-hospital cardiac arrest patients who received cardiopulmonary resuscitation: a systematic review and meta-analysis Crit. Care 24 2020 61 10.1186/s13054-020-2773-2 32087741
2 Virani S.S. Alonso A. Aparicio H.J. Benjamin E.J. Bittencourt M.S. Callaway C.W. Heart disease and stroke statistics-2021 update: a report from the American heart association Circulation 143 2021 e254 e743 10.1161/cir.0000000000000950 33501848
3 Chan P.S. McNally B. Tang F. Kellermann A. Recent trends in survival from out-of-hospital cardiac arrest in the United States Circulation 130 2014 1876 1882 10.1161/circulationaha.114.009711 25399396
4 Park J.S. Lee B.K. Ko S.K. Ro Y.S. Recent status of sudden cardiac arrests in emergency medical facilities: a report from the National Emergency Department Information System (NEDIS) of Korea, 2018-2022 Clin Exp Emerg Med 10 2023 S36 s41 10.15441/ceem.23.154 37967861
5 Cha K.C. Hwang S.O. The future of resuscitation Clin Exp Emerg Med 10 2023 1 4 10.15441/ceem.23.008 36796781
6 Soar J. Böttiger B.W. Carli P. Couper K. Deakin C.D. Djärv T. European resuscitation council guidelines 2021: adult advanced life support Resuscitation 161 2021 115 151 10.1016/j.resuscitation.2021.02.010 33773825
7 Panchal A.R. Bartos J.A. Cabañas J.G. Donnino M.W. Drennan I.R. Hirsch K.G. Part 3: adult basic and advanced life support: 2020 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care Circulation 142 2020 S366 s468 10.1161/cir.0000000000000916 33081529
8 Montford J.R. Linas S. How dangerous is hyperkalemia? J. Am. Soc. Nephrol. 28 2017 3155 3165 10.1681/asn.2016121344 28778861
9 Iseki K. Uehara H. Nishime K. Tokuyama K. Yoshihara K. Kinjo K. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients Am. J. Kidney Dis. 28 1996 541 548 10.1016/s0272-6386(96)90465-5 8840944
10 Shida H. Matsuyama T. Iwami T. Okabayashi S. Yamada T. Hayakawa K. Serum potassium level on hospital arrival and survival after out-of-hospital cardiac arrest: the CRITICAL study in Osaka, Japan Eur Heart J Acute Cardiovasc Care 9 2020 10.1177/2048872619848883 S175-s83
11 Bhattaram S. Shinde V. Hm A. Star in the storm: percutaneous stellate ganglion blockade for drug-refractory electrical storm in the emergency department Clin Exp Emerg Med 10 2023 122 124 10.15441/ceem.22.404 36787900
12 Greenberg A. Hyperkalemia: treatment options Semin. Nephrol. 18 1998 46 57 9459288
13 Forbes G.B. Lewis A.M. Total sodium, potassium and chloride in adult man J. Clin. Invest. 35 1956 596 600 10.1172/jci103313 13319495
14 Sterns R.H. Cox M. Feig P.U. Singer I. Internal potassium balance and the control of the plasma potassium concentration Medicine (Baltim.) 60 1981 339 354 10.1097/00005792-198109000-00002
15 Hollander-Rodriguez J.C. Calvert J.F. Jr. Hyperkalemia Am. Fam. Physician 73 2006 283 290 16445274
16 Evans K.J. Greenberg A. Hyperkalemia: a review J. Intensive Care Med. 20 2005 272 290 10.1177/0885066605278969 16145218
17 Spodick D.H. Effects of severe hyperkalemia Am. Heart Hosp. J. 6 2008 68 10.1111/j.1751-7168.2008.07777.x 18256562
18 Mattu A. Brady W.J. Robinson D.A. Electrocardiographic manifestations of hyperkalemia Am. J. Emerg. Med. 18 2000 721 729 10.1053/ajem.2000.7344 11043630
19 Littmann L. Gibbs M.A. Electrocardiographic manifestations of severe hyperkalemia J. Electrocardiol. 51 2018 814 817 10.1016/j.jelectrocard.2018.06.018 30177318
20 Mushiyakh Y. Dangaria H. Qavi S. Ali N. Pannone J. Tompkins D. Treatment and pathogenesis of acute hyperkalemia J. Community Hosp. Intern. Med. Perspect. 1 2011 10.3402/jchimp.v1i4.7372
21 Kette F. Ghuman J. Parr M. Calcium administration during cardiac arrest: a systematic review Eur. J. Emerg. Med. 20 2013 72 78 10.1097/MEJ.0b013e328358e336 22990036
22 Wang C.H. Huang C.H. Chang W.T. Tsai M.S. Yu P.H. Wu Y.W. The effects of calcium and sodium bicarbonate on severe hyperkalaemia during cardiopulmonary resuscitation: a retrospective cohort study of adult in-hospital cardiac arrest Resuscitation 98 2016 105 111 10.1016/j.resuscitation.2015.09.384 26410570
23 Kawano T. Grunau B. Scheuermeyer F.X. Gibo K. Dick W. Fordyce C.B. Prehospital sodium bicarbonate use could worsen long term survival with favorable neurological recovery among patients with out-of-hospital cardiac arrest Resuscitation 119 2017 63 69 10.1016/j.resuscitation.2017.08.008 28802878
24 Geng S. Green E.F. Kurz M.C. Rivera J.V. Sodium bicarbonate administration and subsequent potassium concentration in hyperkalemia treatment Am. J. Emerg. Med. 50 2021 132 135 10.1016/j.ajem.2021.07.032 34364111
25 Vukmir R.B. Katz L. Sodium bicarbonate improves outcome in prolonged prehospital cardiac arrest Am. J. Emerg. Med. 24 2006 156 161 10.1016/j.ajem.2005.08.016 16490643
26 Ahn S. Kim Y.J. Sohn C.H. Seo D.W. Lim K.S. Donnino M.W. Sodium bicarbonate on severe metabolic acidosis during prolonged cardiopulmonary resuscitation: a double-blind, randomized, placebo-controlled pilot study J. Thorac. Dis. 10 2018 2295 2302 10.21037/jtd.2018.03.124 29850134
27 Meaney P.A. Bobrow B.J. Mancini M.E. Christenson J. de Caen A.R. Bhanji F. Cardiopulmonary resuscitation quality: [corrected] improving cardiac resuscitation outcomes both inside and outside the hospital: a consensus statement from the American Heart Association Circulation 128 2013 417 435 10.1161/CIR.0b013e31829d8654 23801105
28 Halperin H.R. Tsitlik J.E. Guerci A.D. Mellits E.D. Levin H.R. Shi A.Y. Determinants of blood flow to vital organs during cardiopulmonary resuscitation in dogs Circulation 73 1986 539 550 10.1161/01.cir.73.3.539 3948359
29 Reynolds J.C. Grunau B.E. Rittenberger J.C. Sawyer K.N. Kurz M.C. Callaway C.W. Association between duration of resuscitation and favorable outcome after out-of-hospital cardiac arrest: implications for prolonging or terminating resuscitation Circulation 134 2016 2084 2094 10.1161/circulationaha.116.023309 27760796
30 Goldberger Z.D. Chan P.S. Berg R.A. Kronick S.L. Cooke C.R. Lu M. Duration of resuscitation efforts and survival after in-hospital cardiac arrest: an observational study Lancet 380 2012 1473 1481 10.1016/s0140-6736(12)60862-9 22958912
31 Goto Y. Funada A. Goto Y. Relationship between the duration of cardiopulmonary resuscitation and favorable neurological outcomes after out-of-hospital cardiac arrest: a prospective, nationwide, population-based cohort study J. Am. Heart Assoc. 5 2016 e002819 10.1161/jaha.115.002819
